Loading…

Browse All Grants

20,252 grants found

Filters
Reset

Showing 1,0011,020 of 20,252 grants

Active TRAINING, INDIVIDUAL
Unveiling how the molecular landscape of TNBC sculps intratumoral macrophage origin and function
NATIONAL CANCER INSTITUTE Baylor College of Medicine United States 2024 – 2026

ABSTRACT/PROJECT SUMMARY. Triple-negative breast cancer (TNBC) is a heterogenous set of diseases and is considered one of the most aggressive breast cancer subtypes. TNBC lack of w...

$519.7K
USD
Active TRAINING, INDIVIDUAL
Characterizing and Overcoming MHC-I-Mediated Immune Evasion in Triple-Negative Breast Cancer
NATIONAL CANCER INSTITUTE University of North Carolina Chapel Hill United States 2024 – 2027

PROJECT SUMMARY Breast cancer is estimated to be the most diagnosed cancer in American women and account for 15% of female cancer-related deaths in 2023. Triple-negative breast can...

$400.6K
USD
Active TRAINING, INDIVIDUAL
Mechanistic examination and inhibitor targeting of nutrient scavenging for the treatment of pancreatic cancer
NATIONAL CANCER INSTITUTE University of North Carolina Chapel Hill United States 2024 – 2027

Project Summary Abstract Alteration of essential metabolic pathways is a major mechanism by which oncogenic KRAS promotes tumor development and growth in pancreatic ductal adenocar...

$400.6K
USD
Active NON-SBIR/STTR RPGS
Testing ATAD2 as a new therapeutic target for advanced prostate cancer
NATIONAL CANCER INSTITUTE University of California Los Angeles United States 2024 – 2029

PROJECT SUMMARY/ABSTRACT Prostate cancer is the second leading cause of male cancer death. Advanced prostate cancer, whether present at the time of diagnosis or arising after treat...

$5.63M
USD
Completed TRAINING, INDIVIDUAL
Investigating the Role of Diet and ACSS2 in Metabolic and Epigenetic Regulation of Colorectal Cancer
NATIONAL CANCER INSTITUTE University of Pennsylvania United States 2024 – 2025

PROJECT SUMMARY/ABSTRACT Colorectal cancer (CRC) is a leading cause of cancer mortality and is significantly affected by multifactorial influences including host genetic and epigen...

$366.6K
USD
Completed OTHER RESEARCH-RELATED
The crosstalk between obesity-induced fatty liver and liver metastasis
NATIONAL CANCER INSTITUTE Sloan-Kettering Inst Can Research United States 2024 – 2024

PROJECT SUMMARY/ABSTRACT CANDIDATE: As a postdoctoral fellow in Dr. Scott Lowe’s lab at MSKCC, my research focuses on the contribution of obesity-induced non-alcoholic fatty liver...

$1.39M
USD
Active OTHER RESEARCH-RELATED
Integrating Electronic Patient-Reported Outcomes into Discharge Planning
NATIONAL CANCER INSTITUTE Sloan-Kettering Inst Can Research United States 2024 – 2029

PROJECT SUMMARY A prolonged hospital stay after cancer surgery is a common but potentially avoidable problem that negatively impacts quality of care. Goal-directed pathways for dis...

$2.1M
USD
Active NON-SBIR/STTR RPGS
Role of Th2 cytokines in progenitor-mediated formation of tumor lymphatics
NATIONAL CANCER INSTITUTE Southern Illinois University Sch of Med United States 2024 – 2027

PROJECT SUMMARY/ABSTRACT Role of Th2 cytokines in progenitor-mediated formation of tumor lymphatics Lymph node metastasis, a common event in breast cancer, is a strong indicator of...

$4.46M
USD
Active NON-SBIR/STTR RPGS
A novel cellular identity regulatory pathway that drives anokis resistance-mediated TNBC growth and metastasis
NATIONAL CANCER INSTITUTE University of Alabama At Birmingham United States 2024 – 2026

Women in the United States have a 1 in 8 PROJECT SUMMARY lifetime risk of developing breast cancer. Among the various breast cancer subtypes, triple-negative breast cancer (TNBC) c...

$1.49M
USD
Active NON-SBIR/STTR RPGS
Defining the Mechanistic Basis of Bacterial Androgen Production in Dampening Anti-Tumor Immunity and Promoting Resistance to Androgen Receptor Axis-Targeted Therapies for Metastatic Prostate Cancer
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2024 – 2029

Project Summary/Abstract There is increasing evidence over the past decade that the composition of the gut microbiome is important for cancer therapy effectiveness including chemot...

$6.55M
USD
Active NON-SBIR/STTR RPGS
Promoting Effective Clinical Communication about Sexual Health after Gynecologic Cancer: A Randomized Controlled Trial of a Patient-Focused Intervention
NATIONAL CANCER INSTITUTE Research Inst of Fox Chase Can Ctr United States 2024 – 2029

PROJECT SUMMARY Sexual problems are common, distressing and persistent for patients with gynecologic cancer (GC). Yet most patients with GC who experience sexual concerns do not ra...

$4.75M
USD
Active OTHER RESEARCH-RELATED
Learning features of optimal CAR T cells for LBCL from patient data
NATIONAL CANCER INSTITUTE Stanford University United States 2024 – 2026

PROJECT SUMMARY/ABSTRACT Chimeric antigen receptor (CAR) T cells have emerged as breakthrough treatments for patients with hematologic malignancies, earning 12 approvals from the U...

$1.71M
USD
Active OTHER RESEARCH-RELATED
Understanding mechanisms of impaired immunity in the AML bone marrow
NATIONAL CANCER INSTITUTE Sloan-Kettering Inst Can Research United States 2024 – 2029

PROJECT SUMMARY/ABSTRACT Immune-based treatments for acute myeloid leukemia (AML), an aggressive hematologic malignancy that remains fatal for over half of the 20,000 patients diag...

$3.04M
USD
Active TRAINING, INDIVIDUAL
Decoding the Molecular Basis of Dysregulated Cleavage and Polyadenylation in Myeloid Malignancies - Resubmission - 1
NATIONAL CANCER INSTITUTE New York University School of Medicine United States 2024 – 2028

PROJECT SUMMARY This proposal aims to investigate dysregulation of alternative polyadenylation (APA) in acute myeloid leukemia (AML). Dysregulation of APA has been identified in he...

$416.1K
USD
Active NON-SBIR/STTR RPGS
Multi-cohort validation of machine learning radiogenomic models (ML-RGx) to predict late toxicity in prostate cancer
NATIONAL CANCER INSTITUTE Medical College of Wisconsin United States 2024 – 2029

PROJECT SUMMARY Radiotherapy is a cornerstone of treatment for prostate cancer, but radiation-related genitourinary (GU) and gastrointestinal (GI) toxicities can negatively impact...

$5.89M
USD
Active NON-SBIR/STTR RPGS
Multi-parametric Perfusion MRI for Therapy Response Assessment in Brain Cancer
NATIONAL CANCER INSTITUTE St. Joseph'S Hospital and Medical Center United States 2024 – 2027

The long-term goal of this program is to improve patient care by optimizing and validating quantitative magnetic resonance imaging methods for the early prediction of brain cancer...

$4.84M
USD
Active TRAINING, INDIVIDUAL
Base editing to elucidate RAF regulation and signaling
NATIONAL CANCER INSTITUTE Harvard University United States 2024 – 2027

Project Summary Mitogen activated protein kinase (MAPK) signaling regulates cell growth in normal cells and is frequently overactivated in cancer. Within this pathway, RAF kinases...

$416.6K
USD
Active NON-SBIR/STTR RPGS
Targeting mTORC1 translational control in FOXO1 fusion positive rhabdomyosarcoma
NATIONAL CANCER INSTITUTE University of California, San Francisco United States 2024 – 2029

PROJECT SUMMARY PAX3-FOXO1 and related fusions create oncogenic transcription factors that remodel chromatin to drive a subset of childhood rhabdomyosarcoma (RMS) with dismal cure...

$4.82M
USD
Active TRAINING, INDIVIDUAL
PIK3C2A is a vulnerable immunotherapeutic target in triple-negative breast cancer combination therapy
NATIONAL CANCER INSTITUTE Indiana University Indianapolis United States 2024 – 2028

PROJECT SUMMARY Treatment options for triple-negative breast cancer (TNBC) have been very limited. However, specific molecular features such as high PD-L1 expression, elevated tumo...

$480.7K
USD
Active TRAINING, INDIVIDUAL
Immunosuppressive impact of the GPCR/MALT1 protease axis in triple-negative breast cancer
NATIONAL CANCER INSTITUTE University of Pittsburgh At Pittsburgh United States 2024 – 2028

PROJECT SUMMARY/ABSTRACT Breast cancer is the most common cancer in women. Triple-negative breast cancer (TNBC) lacks expression of estrogen receptor (ER-), progesterone receptor (...

$539.7K
USD